Mapping and Outcome Implications of Left Atrial Low Voltage Regions as Determined by a Novel 122-electrode Spherical Mapping and Ablation Catheter
Europace · 07.11.2026
DOI: 10.1093/europace/euag315 ↗Kurz gefasst
Fachartikel in der Zeitschrift Europace, online erschienen am 07.11.2026. Verfasst von Atul Verma und 13 weiteren Autor:innen. Beteiligte Einrichtung: McGill University Health Centre, Montreal, Canada. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aims
A novel 122-electrode spherical mapping/pulsed field ablation (PFA) device is known to effectively ablate atrial fibrillation (AF). The aim of this study is threshold optimization of LVA for the unique geometry of the Globe electrodes and the prognostic association, to evaluate if the extent of low voltage areas could predict recurrence. Methods and Results The PULSAR study was an IDE trial of 183 patients undergoing first-time paroxysmal AF ablation with one-year outcomes of any atrial arrhythmia. During this study, a subset of patients (n=82) had detailed pre-ablation voltage maps performed with the catheter. Pulmonary vein isolation (PVI) was then performed with PFA. Patients were followed with weekly transtelephonic monitoring, ECG, and Holters at 3, 6, and 12 months. Recurrence was defined as any atrial arrhythmia (AA) > 30 seconds. Receiver operator curve (ROC) analysis revealed that a low voltage threshold of 1.0 mV had the highest value (0.735). The percentage LVA surface area resulting from a threshold of 1.0 mV that predicted AA recurrence was 11.6%. Univariate and multivariate analysis revealed the percentage LVA was the strongest predictor of AA recurrence. The 12-month freedom from AA was 84.6% and 52.9% for subjects under and over the low voltage area threshold respectively.
Conclusions
A voltage threshold of 1.0 mV is proposed as a threshold for defining LVA using the spherical catheter, but a range of approximately 0.5-1.5 mV yielded similar performance. Increased low voltage area in the pre-ablation atrial map was associated with a higher risk of AA recurrence.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- McGill University Health Centre, Montreal, Canada.
- Westpfalz Hospital, Kaiserslautern, Germany.
- Johns Hopkins Hospital, Baltimore, MD, USA.
- St. Bernards Medical Center and Arrhythmia Research Group, Jonesboro, AR, USA.
- Clinic for Electrophysiology, Herz- und Diabeteszentrum NRW, Ruhr-University Bochum, Bad Oeynhausen, Germany.
- Cleveland Clinic, Cleveland, OH, USA.
ORCID-Profile: Atul Verma, Hans Kottkamp, Hugh Calkins, Devi G Nair, Philipp Sommer, Ayman A Hussein, Petr Neuzil, Saumil Oza, Christopher Woods, Marc W Deyell, Jose Osorio, Vivek Y Reddy
Zitieren
APA
Verma, A., Kottkamp, H., Calkins, H., Nair, D. G., Sommer, P., Hussein, A. A., Schumacher, B., Dukkipati, S., Neuzil, P., Oza, S., Woods, C., Deyell, M. W., Osorio, J., & Reddy, V. Y. (2026). Mapping and Outcome Implications of Left Atrial Low Voltage Regions as Determined by a Novel 122-electrode Spherical Mapping and Ablation Catheter. Europace. https://doi.org/10.1093/europace/euag315
Vancouver
Verma A, Kottkamp H, Calkins H, Nair DG, Sommer P, Hussein AA, et al. Mapping and Outcome Implications of Left Atrial Low Voltage Regions as Determined by a Novel 122-electrode Spherical Mapping and Ablation Catheter. Europace. 2026. doi:10.1093/europace/euag315
BibTeX
@article{Verma2026,
author = {Verma, Atul and Kottkamp, Hans and Calkins, Hugh and Nair, Devi G and Sommer, Philipp and Hussein, Ayman A and Schumacher, Burghard and Dukkipati, Srinivas and Neuzil, Petr and Oza, Saumil and Woods, Christopher and Deyell, Marc W and Osorio, Jose and Reddy, Vivek Y},
title = {Mapping and Outcome Implications of Left Atrial Low Voltage Regions as Determined by a Novel 122-electrode Spherical Mapping and Ablation Catheter},
journal = {Europace},
year = {2026},
doi = {10.1093/europace/euag315}
}
EUVIMED